CD274 and neoplasm: For example, combination strategies that target multiple aspects of the immune response (e.g., PD-1/PD-L1 and CTLA-4 pathways) or tumor cells themselves (e.g., tyrosine kinase inhibitors, BRAF inhibitors, radiotherapy) could provide benefits for patients with advanced thyroid disease.